Specialist Dr. Orcun Can

Academic Title :

Specialist Dr.

Department	Work location
Cancer Treatment Department	Liv Vadistanbul

Specialist Dr. Orcun Can is a dedicated specialist in MEDICAL ONCOLOGY at the department of medical oncology in Liv Hospital Vadistanbul. He has extensive clinical and academic expertise in diagnosing and managing various cancer types using advanced immunotherapy and targeted therapies since his graduation in 2009.

Education and Academic Qualifications

Çukurova University Faculty of Medicine (2003–2009)
Istanbul Medeniyet University Göztepe Training and Research Hospital – Internal Medicine Specialist (2009–2014)
SBÜ Okmeydanı Training and Research Hospital – Medical Oncology Subspecialty (2015–2018)
Oxford University – Clinical Research Fellowship with Prof. David J. Kerr on Metastatic Colorectal Cancer (2015)
Klinikum Oldenburg – Clinical Research Fellowship with Prof. Claus-Henning Köhne & Prof. Frank Griesinger on Thoracic and Gastrointestinal Oncology (2017)

Areas of Interest

Breast cancer treatment in Turkey
Thoracic oncology and lung cancer treatment in Turkey
Gastrointestinal system cancers
Gynecological cancers
Urogenital system cancers
Immunotherapy and targeted therapies
Molecular oncology and precision medicine
Biomarkers and liquid biopsy

Work Experience

Kırklareli Pınarhisar State Hospital – Internal Medicine Specialist
SBÜ Okmeydanı Training and Research Hospital – Medical Oncology Subspecialty Resident
Nevşehir State Hospital – Medical Oncology Specialist
Prof. Dr. Cemil Taşcıoğlu City Hospital – Medical Oncology Specialist
Istinye University Liv Hospital – Medical Oncology Specialist
Acibadem Maslak Hospital – Medical Oncology Specialist
Liv Hospital Vadistanbul – Medical Oncology Specialist (2026–present)

Professional Affiliations & Memberships

European Society for Medical Oncology (ESMO)
American Society for Clinical Oncology (ASCO)
Turkish Medical Oncology Association (TTOD)

Research & Publications

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium (2023)
Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment (2025)
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study (2022)
Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors (2019)
Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study (2024)

Visits : 75